Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Sequenom Q1 Revenue Up on Increased Costs, Widened Losses

NEW YORK, April 30 - Sequenom today reported higher first-quarter revenues and increased net losses as strong demand for its genotyping systems and genetic services was outweighed by the increasing expense of the company's gene-discovery efforts.

 

Revenues for the quarter ended March 31 were $8.6 million compared with $5.2 million during the same period last year. Sequenom sold 11 MassARRAY systems during the quarter, it said.

 

Costs and expenses also climbed to $21 million in the first quarter 2002 from $14.2 million year over year.

 

Sequenom's net loss, including accounting changes, was $3.41 per diluted common share, totaling $127.9 million. Excluding those changes, loss for the quarter was $11 million, or $.29 per diluted share, compared with $7 million, or $.29 per diluted share, during the first quarter 2001.

 

The company held cash, cash equivalents, and short-term investments of $126.1 million as of March 31.

 

For more information, click here.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.